Form 4: TELA Bio Director Vincent Burgess Receives Significant Equity Grant, Aligning Interests with Shareholders

TELA Bio, Inc. Director Vincent J. Burgess was granted 7,950 restricted stock units and 11,700 stock options, aligning his compensation with the company's performance and shareholder interests.

Summary

• Vincent J. Burgess, a Director of TELA Bio, Inc. (TELA), reported the acquisition of 7,950 shares of Common Stock in the form of Restricted Stock Units (RSUs) on May 28, 2025, at a price of $0 per share.
• Additionally, Mr. Burgess acquired 11,700 stock options with an exercise price of $1.39 per share on May 28, 2025.
• Following these transactions, Mr. Burgess beneficially owns 23,330 shares of Common Stock directly and 11,700 stock options directly.
• Both the restricted stock units and stock options are subject to vesting conditions, which include the earlier of May 28, 2026, the next annual meeting of stockholders, or a Change in Control, contingent upon Mr. Burgess's continued service.
• The stock options have an expiration date of May 28, 2035.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the filing indicates an insider's increased stake and alignment with shareholder interests through equity grants, which is generally viewed favorably.

Positives

• The grant of restricted stock units and stock options to Director Vincent J. Burgess aligns his financial interests directly with the long-term performance of TELA Bio, Inc. and its shareholders.
• Equity-based compensation is a common practice that incentivizes directors to contribute to the company's growth and value creation.
• The acquisition of shares and options by an insider can be viewed as a vote of confidence in the company's future prospects.

Risks

• The vesting of both the restricted stock units and stock options is contingent upon Mr. Burgess's continued service, meaning the benefits are not guaranteed if his service terminates prior to vesting.
• The value of the stock options is dependent on the future market price of TELA Bio's common stock exceeding the exercise price of $1.39; if the stock price remains below this, the options may hold no intrinsic value.
• The vesting schedule includes a 'Change in Control' clause, which could accelerate vesting under certain acquisition scenarios, potentially impacting long-term alignment if a change of control occurs early.

Future Outlook

The equity grants are designed to incentivize the director's continued service and align his interests with the company's long-term performance, with vesting periods extending to at least May 28, 2026, or the next annual meeting of stockholders.

Management Comments

• The grant of restricted stock units and stock options to Director Vincent J. Burgess reflects the company's compensation strategy to retain and incentivize key personnel through equity participation, as outlined in the Issuer's Amended and Restated 2019 Equity Incentive Plan.

Industry Context

Equity grants, such as restricted stock units and stock options, are a standard component of executive and director compensation packages across various industries, including the biotechnology and medical device sectors where TELA Bio operates. This practice aims to align the interests of company leadership with those of shareholders by tying compensation to company performance and stock value.

Comparison to Industry Standards

• The use of restricted stock units and stock options for director compensation is a common and widely accepted practice within the U.S. public company landscape, including comparable companies in the medical technology and healthcare sectors.
• The vesting conditions, including continued service and acceleration upon a Change in Control, are typical provisions found in equity incentive plans across global benchmarks, designed to balance retention with performance incentives.

Corporate Governance

Related Party Transactions

• The grant of 7,950 restricted stock units and 11,700 stock options to Vincent J. Burgess, a Director of TELA Bio, Inc., constitutes a related party transaction as it involves the company and an insider.

Stakeholder Impact

• Shareholders: The grants align the director's interests with shareholders, potentially leading to more focused efforts on increasing shareholder value.
• Employees: While not directly impacting general employees, such grants to leadership can signal stability and long-term vision within the company.
• Management: The grants incentivize the director to remain engaged and contribute to the company's strategic direction and operational success.

Next Steps

• Continued service of Vincent J. Burgess as a Director of TELA Bio, Inc. to fulfill vesting conditions.
• Monitoring of TELA Bio's stock performance, which will impact the value of the granted options and RSUs.

Key Dates

Keywords

TELA Bio, Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Director Compensation, Equity Grant, Corporate Governance, Beneficial Ownership, SEC Filing